APO Research
Talk to an analyst

APO RESEARCH · REPORT

CCL14 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CCL14 Antibody Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchCCL14 Antibody Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal CCL14 Antibody Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal CCL14 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CCL14 Antibody Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal CCL14 Antibody Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global CCL14 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CCL14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CCL14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CCL14 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CCL14 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CCL14 Antibody market include Thermo Fisher Scientific, Boster Biological Technology, Sino Biological, Inc., MyBiosource, Inc., LifeSpan BioSciences, Inc, Creative Diagnostics, Creative Biolabs, Cepham Life Sciences and Bio-Techne, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global CCL14 Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CCL14 Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CCL14 Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the CCL14 Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

CCL14 Antibody Segment by Company

Thermo Fisher Scientific

Boster Biological Technology

Sino Biological, Inc.

MyBiosource, Inc.

LifeSpan BioSciences, Inc

Creative Diagnostics

Creative Biolabs

Cepham Life Sciences

Bio-Techne

Biorbyt

Abbexa

​​Abcam

CCL14 Antibody Segment by Type

Monoclonal Antibody

Polyclonal Antibody

CCL14 Antibody Segment by Application

Western Blot

Flow Cytometry

ELISA

Immunoprecipitation

Immunofluorescence

Other

CCL14 Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CCL14 Antibody status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions CCL14 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CCL14 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze CCL14 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CCL14 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CCL14 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CCL14 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the CCL14 Antibody market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CCL14 Antibody industry.

Chapter 3: Detailed analysis of CCL14 Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of CCL14 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of CCL14 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CCL14 Antibody Industry Trends Table 2. CCL14 Antibody Industry Drivers Table 3. CCL14 Antibody Industry Opportunities and Challenges Table 4. CCL14 Antibody Industry Restraints Table 5. Global CCL14 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CCL14 Antibody Revenue Share by Company (2021-2026) Table 7. Global CCL14 Antibody Sales Volume by Company (k units) & (2021-2026) Table 8. Global CCL14 Antibody Sales Volume Share by Company (2021-2026) Table 9. Global CCL14 Antibody Average Price (US$/unit) of Company (2021-2026) Table 10. Global CCL14 Antibody Company Ranking, (2024-2026) & (USD Million) Table 11. Global CCL14 Antibody Key Company Manufacturing Base & Headquarters Table 12. Global CCL14 Antibody Company, Product Type & Application Table 13. Global CCL14 Antibody Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global CCL14 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monoclonal Antibody Table 18. Significant Companies of Polyclonal Antibody Table 19. Global CCL14 Antibody Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global CCL14 Antibody Sales Volume by Type (2021-2026) & (k units) Table 21. Global CCL14 Antibody Sales Volume by Type (2027-2032) & (k units) Table 22. Global CCL14 Antibody Sales Volume Share by Type (2021-2026) Table 23. Global CCL14 Antibody Sales Volume Share by Type (2027-2032) Table 24. Global CCL14 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global CCL14 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global CCL14 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global CCL14 Antibody Sales Value Share by Type (2021-2026) Table 28. Global CCL14 Antibody Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Western Blot Table 30. Significant Companies of Flow Cytometry Table 31. Significant Companies of ELISA Table 32. Significant Companies of Immunoprecipitation Table 33. Significant Companies of Immunofluorescence Table 34. Significant Companies of Other Table 35. Global CCL14 Antibody Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global CCL14 Antibody Sales Volume by Application (2021-2026) & (k units) Table 37. Global CCL14 Antibody Sales Volume by Application (2027-2032) & (k units) Table 38. Global CCL14 Antibody Sales Volume Share by Application (2021-2026) Table 39. Global CCL14 Antibody Sales Volume Share by Application (2027-2032) Table 40. Global CCL14 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global CCL14 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global CCL14 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global CCL14 Antibody Sales Value Share by Application (2021-2026) Table 44. Global CCL14 Antibody Sales Value Share by Application (2027-2032) Table 45. Global CCL14 Antibody Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global CCL14 Antibody Sales by Region (2021-2026) & (k units) Table 47. Global CCL14 Antibody Sales Market Share by Region (2021-2026) Table 48. Global CCL14 Antibody Sales by Region (2027-2032) & (k units) Table 49. Global CCL14 Antibody Sales Market Share by Region (2027-2032) Table 50. Global CCL14 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global CCL14 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global CCL14 Antibody Sales Value Share by Region (2021-2026) Table 53. Global CCL14 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global CCL14 Antibody Sales Value Share by Region (2027-2032) Table 55. Global CCL14 Antibody Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global CCL14 Antibody Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global CCL14 Antibody Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global CCL14 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global CCL14 Antibody Sales by Country (2021-2026) & (k units) Table 60. Global CCL14 Antibody Sales Market Share by Country (2021-2026) Table 61. Global CCL14 Antibody Sales by Country (2027-2032) & (k units) Table 62. Global CCL14 Antibody Sales Market Share by Country (2027-2032) Table 63. Global CCL14 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global CCL14 Antibody Sales Value Market Share by Country (2021-2026) Table 65. Global CCL14 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global CCL14 Antibody Sales Value Market Share by Country (2027-2032) Table 67. Thermo Fisher Scientific Company Information Table 68. Thermo Fisher Scientific Business Overview Table 69. Thermo Fisher Scientific CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Thermo Fisher Scientific CCL14 Antibody Product Portfolio Table 71. Thermo Fisher Scientific Recent Development Table 72. Boster Biological Technology Company Information Table 73. Boster Biological Technology Business Overview Table 74. Boster Biological Technology CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Boster Biological Technology CCL14 Antibody Product Portfolio Table 76. Boster Biological Technology Recent Development Table 77. Sino Biological, Inc. Company Information Table 78. Sino Biological, Inc. Business Overview Table 79. Sino Biological, Inc. CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Sino Biological, Inc. CCL14 Antibody Product Portfolio Table 81. Sino Biological, Inc. Recent Development Table 82. MyBiosource, Inc. Company Information Table 83. MyBiosource, Inc. Business Overview Table 84. MyBiosource, Inc. CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. MyBiosource, Inc. CCL14 Antibody Product Portfolio Table 86. MyBiosource, Inc. Recent Development Table 87. LifeSpan BioSciences, Inc Company Information Table 88. LifeSpan BioSciences, Inc Business Overview Table 89. LifeSpan BioSciences, Inc CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. LifeSpan BioSciences, Inc CCL14 Antibody Product Portfolio Table 91. LifeSpan BioSciences, Inc Recent Development Table 92. Creative Diagnostics Company Information Table 93. Creative Diagnostics Business Overview Table 94. Creative Diagnostics CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Creative Diagnostics CCL14 Antibody Product Portfolio Table 96. Creative Diagnostics Recent Development Table 97. Creative Biolabs Company Information Table 98. Creative Biolabs Business Overview Table 99. Creative Biolabs CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Creative Biolabs CCL14 Antibody Product Portfolio Table 101. Creative Biolabs Recent Development Table 102. Cepham Life Sciences Company Information Table 103. Cepham Life Sciences Business Overview Table 104. Cepham Life Sciences CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Cepham Life Sciences CCL14 Antibody Product Portfolio Table 106. Cepham Life Sciences Recent Development Table 107. Bio-Techne Company Information Table 108. Bio-Techne Business Overview Table 109. Bio-Techne CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Bio-Techne CCL14 Antibody Product Portfolio Table 111. Bio-Techne Recent Development Table 112. Biorbyt Company Information Table 113. Biorbyt Business Overview Table 114. Biorbyt CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Biorbyt CCL14 Antibody Product Portfolio Table 116. Biorbyt Recent Development Table 117. Abbexa Company Information Table 118. Abbexa Business Overview Table 119. Abbexa CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Abbexa CCL14 Antibody Product Portfolio Table 121. Abbexa Recent Development Table 122. ​​Abcam Company Information Table 123. ​​Abcam Business Overview Table 124. ​​Abcam CCL14 Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. ​​Abcam CCL14 Antibody Product Portfolio Table 126. ​​Abcam Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. CCL14 Antibody Distributors List Table 130. CCL14 Antibody Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. CCL14 Antibody Product Image Figure 2. Global CCL14 Antibody Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CCL14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 4. Global CCL14 Antibody Sales (2021-2032) & (k units) Figure 5. Global CCL14 Antibody Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global CCL14 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monoclonal Antibody Image Figure 10. Polyclonal Antibody Image Figure 11. Global CCL14 Antibody Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global CCL14 Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global CCL14 Antibody Sales Volume Share by Type (2021-2032) Figure 14. Global CCL14 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global CCL14 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global CCL14 Antibody Sales Value Share by Type (2021-2032) Figure 17. Western Blot Image Figure 18. Flow Cytometry Image Figure 19. ELISA Image Figure 20. Immunoprecipitation Image Figure 21. Immunofluorescence Image Figure 22. Other Image Figure 23. Global CCL14 Antibody Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global CCL14 Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global CCL14 Antibody Sales Volume Share by Application (2021-2032) Figure 26. Global CCL14 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global CCL14 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global CCL14 Antibody Sales Value Share by Application (2021-2032) Figure 29. Global CCL14 Antibody Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global CCL14 Antibody Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global CCL14 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global CCL14 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America CCL14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 34. North America CCL14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe CCL14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 36. Europe CCL14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific CCL14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific CCL14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America CCL14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 40. South America CCL14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa CCL14 Antibody Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa CCL14 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt CCL14 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt CCL14 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt CCL14 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. CCL14 Antibody Value Chain Figure 128. Manufacturing Cost Structure Figure 129. CCL14 Antibody Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Polyclonal Antibody
Applications
  • Western Blot
  • Flow Cytometry
  • ELISA
  • Immunoprecipitation
  • Immunofluorescence
  • Other
Companies covered
  • Thermo Fisher Scientific
  • Boster Biological Technology
  • Sino Biological, Inc.
  • MyBiosource, Inc.
  • LifeSpan BioSciences, Inc
  • Creative Diagnostics
  • Creative Biolabs
  • Cepham Life Sciences
  • Bio-Techne
  • Biorbyt
  • Abbexa
  • ​​Abcam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global CCL14 Antibody Sales Value (2021-2032)
  4. 1.2.2 Global CCL14 Antibody Sales Volume (2021-2032)
  5. 1.2.3 Global CCL14 Antibody Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 CCL14 Antibody Market Dynamics
  1. 2.1 CCL14 Antibody Industry Trends
  2. 2.2 CCL14 Antibody Industry Drivers
  3. 2.3 CCL14 Antibody Industry Opportunities and Challenges
  4. 2.4 CCL14 Antibody Industry Restraints
3 CCL14 Antibody Market by Company
  1. 3.1 Global CCL14 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global CCL14 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global CCL14 Antibody Sales Volume by Company (2021-2026)
  4. 3.4 Global CCL14 Antibody Average Price by Company (2021-2026)
  5. 3.5 Global CCL14 Antibody Company Ranking (2024-2026)
  6. 3.6 Global CCL14 Antibody Company Manufacturing Base and Headquarters
  7. 3.7 Global CCL14 Antibody Company Product Type and Application
  8. 3.8 Global CCL14 Antibody Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global CCL14 Antibody Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 CCL14 Antibody Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 CCL14 Antibody Market by Type
  1. 4.1 CCL14 Antibody Type Introduction
  2. 4.1.1 Monoclonal Antibody
  3. 4.1.2 Polyclonal Antibody
  4. 4.2 Global CCL14 Antibody Sales Volume by Type
  5. 4.2.1 Global CCL14 Antibody Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CCL14 Antibody Sales Volume by Type (2021-2032)
  7. 4.2.3 Global CCL14 Antibody Sales Volume Share by Type (2021-2032)
  8. 4.3 Global CCL14 Antibody Sales Value by Type
  9. 4.3.1 Global CCL14 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global CCL14 Antibody Sales Value by Type (2021-2032)
  11. 4.3.3 Global CCL14 Antibody Sales Value Share by Type (2021-2032)
5 CCL14 Antibody Market by Application
  1. 5.1 CCL14 Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Flow Cytometry
  4. 5.1.3 ELISA
  5. 5.1.4 Immunoprecipitation
  6. 5.1.5 Immunofluorescence
  7. 5.1.6 Other
  8. 5.2 Global CCL14 Antibody Sales Volume by Application
  9. 5.2.1 Global CCL14 Antibody Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global CCL14 Antibody Sales Volume by Application (2021-2032)
  11. 5.2.3 Global CCL14 Antibody Sales Volume Share by Application (2021-2032)
  12. 5.3 Global CCL14 Antibody Sales Value by Application
  13. 5.3.1 Global CCL14 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global CCL14 Antibody Sales Value by Application (2021-2032)
  15. 5.3.3 Global CCL14 Antibody Sales Value Share by Application (2021-2032)
6 CCL14 Antibody Regional Sales and Value Analysis
  1. 6.1 Global CCL14 Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CCL14 Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global CCL14 Antibody Sales by Region: 2021-2026
  4. 6.2.2 Global CCL14 Antibody Sales by Region (2027-2032)
  5. 6.3 Global CCL14 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global CCL14 Antibody Sales Value by Region (2021-2032)
  7. 6.4.1 Global CCL14 Antibody Sales Value by Region: 2021-2026
  8. 6.4.2 Global CCL14 Antibody Sales Value by Region (2027-2032)
  9. 6.5 Global CCL14 Antibody Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America CCL14 Antibody Sales Value (2021-2032)
  12. 6.6.2 North America CCL14 Antibody Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe CCL14 Antibody Sales Value (2021-2032)
  15. 6.7.2 Europe CCL14 Antibody Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific CCL14 Antibody Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific CCL14 Antibody Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America CCL14 Antibody Sales Value (2021-2032)
  21. 6.9.2 South America CCL14 Antibody Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa CCL14 Antibody Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa CCL14 Antibody Sales Value Share by Country, 2025 VS 2032
7 CCL14 Antibody Country-level Sales and Value Analysis
  1. 7.1 Global CCL14 Antibody Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CCL14 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global CCL14 Antibody Sales by Country (2021-2032)
  4. 7.3.1 Global CCL14 Antibody Sales by Country (2021-2026)
  5. 7.3.2 Global CCL14 Antibody Sales by Country (2027-2032)
  6. 7.4 Global CCL14 Antibody Sales Value by Country (2021-2032)
  7. 7.4.1 Global CCL14 Antibody Sales Value by Country (2021-2026)
  8. 7.4.2 Global CCL14 Antibody Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA CCL14 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada CCL14 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico CCL14 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany CCL14 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France CCL14 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. CCL14 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy CCL14 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain CCL14 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia CCL14 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands CCL14 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries CCL14 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China CCL14 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan CCL14 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea CCL14 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India CCL14 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia CCL14 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia CCL14 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil CCL14 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina CCL14 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile CCL14 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia CCL14 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru CCL14 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia CCL14 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel CCL14 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE CCL14 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey CCL14 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran CCL14 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt CCL14 Antibody Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt CCL14 Antibody Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt CCL14 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific CCL14 Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Boster Biological Technology
  8. 8.2.1 Boster Biological Technology Company Information
  9. 8.2.2 Boster Biological Technology Business Overview
  10. 8.2.3 Boster Biological Technology CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Boster Biological Technology CCL14 Antibody Product Portfolio
  12. 8.2.5 Boster Biological Technology Recent Developments
  13. 8.3 Sino Biological, Inc.
  14. 8.3.1 Sino Biological, Inc. Company Information
  15. 8.3.2 Sino Biological, Inc. Business Overview
  16. 8.3.3 Sino Biological, Inc. CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sino Biological, Inc. CCL14 Antibody Product Portfolio
  18. 8.3.5 Sino Biological, Inc. Recent Developments
  19. 8.4 MyBiosource, Inc.
  20. 8.4.1 MyBiosource, Inc. Company Information
  21. 8.4.2 MyBiosource, Inc. Business Overview
  22. 8.4.3 MyBiosource, Inc. CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MyBiosource, Inc. CCL14 Antibody Product Portfolio
  24. 8.4.5 MyBiosource, Inc. Recent Developments
  25. 8.5 LifeSpan BioSciences, Inc
  26. 8.5.1 LifeSpan BioSciences, Inc Company Information
  27. 8.5.2 LifeSpan BioSciences, Inc Business Overview
  28. 8.5.3 LifeSpan BioSciences, Inc CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 LifeSpan BioSciences, Inc CCL14 Antibody Product Portfolio
  30. 8.5.5 LifeSpan BioSciences, Inc Recent Developments
  31. 8.6 Creative Diagnostics
  32. 8.6.1 Creative Diagnostics Company Information
  33. 8.6.2 Creative Diagnostics Business Overview
  34. 8.6.3 Creative Diagnostics CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Creative Diagnostics CCL14 Antibody Product Portfolio
  36. 8.6.5 Creative Diagnostics Recent Developments
  37. 8.7 Creative Biolabs
  38. 8.7.1 Creative Biolabs Company Information
  39. 8.7.2 Creative Biolabs Business Overview
  40. 8.7.3 Creative Biolabs CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Creative Biolabs CCL14 Antibody Product Portfolio
  42. 8.7.5 Creative Biolabs Recent Developments
  43. 8.8 Cepham Life Sciences
  44. 8.8.1 Cepham Life Sciences Company Information
  45. 8.8.2 Cepham Life Sciences Business Overview
  46. 8.8.3 Cepham Life Sciences CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Cepham Life Sciences CCL14 Antibody Product Portfolio
  48. 8.8.5 Cepham Life Sciences Recent Developments
  49. 8.9 Bio-Techne
  50. 8.9.1 Bio-Techne Company Information
  51. 8.9.2 Bio-Techne Business Overview
  52. 8.9.3 Bio-Techne CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bio-Techne CCL14 Antibody Product Portfolio
  54. 8.9.5 Bio-Techne Recent Developments
  55. 8.10 Biorbyt
  56. 8.10.1 Biorbyt Company Information
  57. 8.10.2 Biorbyt Business Overview
  58. 8.10.3 Biorbyt CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biorbyt CCL14 Antibody Product Portfolio
  60. 8.10.5 Biorbyt Recent Developments
  61. 8.11 Abbexa
  62. 8.11.1 Abbexa Company Information
  63. 8.11.2 Abbexa Business Overview
  64. 8.11.3 Abbexa CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Abbexa CCL14 Antibody Product Portfolio
  66. 8.11.5 Abbexa Recent Developments
  67. 8.12 ​​Abcam
  68. 8.12.1 ​​Abcam Company Information
  69. 8.12.2 ​​Abcam Business Overview
  70. 8.12.3 ​​Abcam CCL14 Antibody Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 ​​Abcam CCL14 Antibody Product Portfolio
  72. 8.12.5 ​​Abcam Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 CCL14 Antibody Value Chain Analysis
  2. 9.1.1 CCL14 Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 CCL14 Antibody Sales Mode & Process
  6. 9.2 CCL14 Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 CCL14 Antibody Distributors
  9. 9.2.3 CCL14 Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst